Actavis CEO Says Health Law May Boost Generics Use

Actavis CEO Says Health Law May Boost Generics Use Play

Feb. 15 (Bloomberg) -- Paul Bisaro, chief executive officer of Actavis Inc., talks about the impact of the U.S. Affordable Care Act on the pharmaceutical industry, so-called biosimilars, generic versions of biotechnology drugs, and the outlook for growth. He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line." (Source: Bloomberg)

blog comments powered by Disqus